References
- Hyttel J. SCH‐23390 ‐ the first selective dopamine D‐1 antagonist. Eur. J. Pharmacol. 1983; 91: 153–154
- Hall H., Farde L., Sedvall G. Human dopamine receptor subtypes ‐ in vitro binding analysis using 3H‐SCH‐23390 and 3H‐raclopride. J. Neural Transm. 1988; 73: 7–21
- Madras B. K., Fahey M. A., Canfield D. R., Spealman R. D. D1 and D2 dopamine receptors in caudate‐putamen of nonhuman primates (Macaca fascicularis). J. Neurochem. 1988; 51: 934–943
- Niznik H. B., Fogel E. L., Chen C. J., Congo D., Brown E. M., Seeman P. Dopamine D1 receptors of the calf parathyroid gland: Identification and characterization. Mol. Pharmacol. 1988; 34: 29–36
- Seeman P., Ulpain C., Grigoriadis D., Pri‐Bar I., Buchman O. Conversion of dopamine D1 receptors from high to low affinity for dopamine. Biochem. Pharmacol. 1985; 34: 151–154
- Hadjiconstantinou M., Neff N. H. Ascorbic acid could be hazardous to your experiments: A commentary on dopamine receptor binding studies with speculation on a role for ascorbic acid in neuronal function. Neuropharmacology 1983; 22: 939–943
- Kayaalp S. O., Neff N. H. Differentiation by ascorbic acid of dopamine agonist and antagonist binding sites in striatum. Life Sci. 1980; 26: 1837–1841
- Leff S., Sibley D. R., Hamblin M., Creese I. Ascorbic acid enables reversible dopamine receptor 3H‐agonist binding. Life Sci. 1981; 29: 2081–2090
- Heikkila R. E., Cabbat F. S., Manzino L. Inhibitory effects of ascorbic acid on the binding of [3H]dopamine antagonists to neostriatal membrane preparations: Relationship to lipid peroxidation. J. Neurochem. 1982; 38: 1000–1006
- Heikkila R. E., Cabbat F. S., Manzino L. Stereospecific binding of 3H‐dopamine in neostriatal membrane preparations: Inhibitory effects of sodium ascorbate. Life Sci. 1983; 32: 2183–2191
- Kayaalp S. O., Rubenstein J. S., Neff N. H. Inhibition of dopamine D‐1 and D‐2 binding sites in neuronal tissue by ascorbate. Neuropharmacology 1981; 20: 409–410
- Leslie F. M., Dunlap C. E., Cox B. M. Ascorbate decreases ligand binding to neurotransmitter receptors. J. Neurochem. 1980; 34: 219–221
- Chan B., Seeman P., Davis A., Madras B. K. Ascorbate injury and EDTA (or manganese) protection of D2‐dopamine receptors. Eur. J. Pharmacol. 1982; 81: 111–116
- Heikkila R. E., Cabbat F. S. Ascorbate‐induced lipid peroxidation and inhibition of [3H]spiroperidol binding in neostriatal membrane preparations. J. Neurochem. 1983; 41: 1384–1392
- Heikkila R. E., Manzino L. Ascorbic acid, redox cycling, lipid peroxidation, and the binding of dopamine receptor antagonists. Ann. N. Y. Acad. Sci. 1987; 498: 63–76
- Madras B. K., Chan B. Modulation of dopamine receptor binding by ascorbic acid. Adv. Biochem. Psychopharmacol. 1983; 37: 275–287
- Sershen H., Debler E. A., Lajtha A. Effect of ascorbic acid on the synaptosomal uptake of [3H]MPP+ [3H]dopamine, and [14C]GABA. J. Neurosci. Res. 1987; 17: 298–301
- Debler E. A., Hashim A., Lajtha A., Sershen H. Ascorbic acid and striatal transport of [3H]1‐methyl‐4‐phenylpyridine (MPP+) and [3H]dopamine. Life Sci. 1988; 42: 2553–2559
- Munson P. J., Rodbard D. LIGAND: A versatile computerized approach for characterization of ligand‐binding systems. Anal. Biochem. 1980; 107: 220–239
- Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951; 193: 265–275